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Clozapine is the only antipsychotic with evidence for efficacy in treatment of resistant schizophrenia but it carries a high side
effect burden. Patient information is provided but may be poorly retained. This study aims to examine the impact of pharmacist
counselling upon patient knowledge of clozapine. Outpatients, aged 18 years and over, attending St. Patrick’s University Hospital,
Dublin, participated in this study between June and August 2015. The intervention consisted of pharmacist counselling on two
occasions one month apart. Knowledge was assessed using a 28-point checklist devised from the currently available clozapine
patient information sources, at baseline and after each counselling session. Ethics approval was obtained. Twenty-five participants
(40% female; mean age 45.1 years, SD 9.82; 64% unemployed, 28% smokers) showed an improvement in knowledge scores of
clozapine from baseline to postcounselling on each occasion with an overall improvement in knowledge score, from baseline to
postcounselling at one month, of 39.43%; 𝑝 < 0.001. This study adds to the evidence that interventions involving pharmacist
counselling can improve patient knowledge, whilst the specific knowledge gained relating to recognition of side effects may help
patients towards more empowerment regarding their treatment.
1. Introduction
Clozapine is an atypical antipsychotic licensed for use in
treatment resistant schizophrenia [1]. It is considered to be
the gold standard, used after the failure of other drugs due
to adverse effects or lack of efficacy [2]. In common with
all medicines, it has a range of possible adverse effects,
from very rare but possibly life threatening agranulocytosis
to the very common troublesome effect of sedation [1]. To
manage their medication well and achieve the optimal risk
benefit balance, patients should be able to identify these
side effects and determine if they may be related to the
drug. Pharmacist counselling is a common and broadly
accepted method of communicating medication information
to patients. A systematic review to determine whether there
is evidence to show that pharmacist counselling improves
patient knowledge about clozapine amongst outpatient clinic
attendees showed a lack of evidence in this area. Five studies
[3–7] involving a range of prescribedmedications and patient
groups were examined. Only one of these was in patients
with schizophrenia [5] and none were in those prescribed
clozapine exclusively further underpinning the need for
more evidence in this area. All studies with one excep-
tion [3] demonstrated improvements in patient knowledge
of their medication as a result of pharmacist counselling
interventions. The exception was a retrospective study where
pharmacists had not specifically been taskedwith counselling
as an intervention. From this review, a single counselling
session was noted to result in improvements in knowledge
between 8 and 18% overall and where three sessions were
undertaken [5] improvements of 43% were achieved. The
significance of these improvements in practice is not known
and there is evidence that, in the absence of reinforcement,
knowledge is lost over time [5, 6].
Limited health literacy (or occurrence of factors associ-
ated with limited health literacy) was found to be associated
with low knowledge about prescribed medication in all of
the reviewed papers. However, the study undertaken in
patients with schizophrenia [5] found illness and medication
factors to be more strongly correlated with poor medication
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knowledge than psychosocial or education-related factors;
therefore patients with schizophreniamay be a unique cohort
when considering medication information needs.
Once discharged fromhospital, patients prescribed cloza-
pine attend an outpatient phlebotomy clinic on a regular
basis as determined by the product license and the Clozaril
Patient Monitoring Service (CPMS) [8] for the duration of
their treatment. Despite being prescribed a medication that
carries some risk and frequent attendance at hospital clinics,
there is no formal structure in place to ensure patients arewell
informed about their medication on an on-going basis. This
research therefore builds on two previous pieces of work (one
looking at the appropriateness of clozapine information given
to patients and addressing this by developing information
leaflets with a higher readability score [9] and another
that demonstrated the benefits of pharmacist counselling in
improving knowledge about warfarin irrespective of baseline
health literacy [6]) in order to identify potential methods of
improving patient knowledge and to assess their impact.This
research therefore aimed to examine the impact of pharma-
cist counselling upon patient knowledge of clozapine with
the primary objective of determining the change in patient
knowledge score after a defined time period and repeated
pharmacist counselling. Secondary objectives of assessing
baseline health literacy in a cohort of outpatients attending a
clozapine clinic using the (Revised) Rapid Estimate of Adult
Literacy in Medicine (REALM-R) and thereafter assessing
if there is any association between variables of interest and
health literacy or the change in patient knowledge were set.
2. Methods
2.1. Study Design. The study was designed as a prospective
interventional study.
2.2. Study Setting and Participants. The study participants
were outpatients attending St. Patrick’s University Hospital
(SPUH), Dublin’s Clozapine Clinics. St. Patrick’s Mental
Health Services is Ireland’s largest, independent (private),
not-for-profit mental health service with a total of 288
adult inpatient beds. There are approximately 2,900 inpatient
admissions per year to the hospital accounting for approxi-
mately 16% of all admissions to Irish Psychiatric Units and
Hospitals in 2012 [10].
2.3. Eligibility. All patients attending the Outpatient Clozap-
ine Clinics at SPUH were approached for participation. All
those agreeable to take part were included in the study. Data
collection was undertaken over an 11-week period from June
to August 2015.
2.4. Inclusion Criteria. Adult (18 years and older) outpatients
attending Outpatient Clozapine Clinics at SPUH who were
deemed clinically well enough to participate in the study by
their treating team were included in the study.
2.5. Exclusion Criteria. Inpatients, those aged less than 18
years, or those unable to provide written informed consent,
were excluded.
2.6. Confidentiality and Ethical Issues. Ethics approval was
obtained from the St. Patrick’s Mental Health Services
Research Ethics Committee. Prescribers were preinformed by
letter to allow time for any objections to inclusion of patients
on clinical grounds; however none were received.
Data were anonymized and the principal investigator
retained an electronic key separately from the anonymized
data on an individually password protected computer. Paper
data were stored securely within the pharmacy department,
which is a restricted access area. No identifiable results left
SPUH premises in paper or electronic format, nor were
they made available to any parties other than the principal
investigator. All documents and electronic data will be
destroyed by shredding and disposal in confidential waste or
erasing electronically one year after final publication of the
study.
2.7. Protocol Procedure Overview. A patient knowledge
checklist was devised by a pharmacist from the currently
available clozapine patient information sources, that is, (i)
the manufacturer’s patient information leaflet (PIL) [11] and
(ii) the “Choice and Medication” (C&M) PIL (designed for
improved usability and readability for patients using mental
health services as they are easily understood by most 12 year
olds) [12]. This checklist included items which ascertained
the patient’s knowledge on a range of areas including (i)
therapeutic uses of clozapine, (ii) common side effects, and
(iii) action to be taken in the event of missed dose. The
patient received a maximum of one point per question and
a maximum of 28 points overall.
Pilot testing of forms and questionnaires was performed
on pharmacy department staff to ensure face validity.
Several pharmacists were involved in patient counselling
to increase generalizability of pharmacist counselling and
reduce the possibility of interviewer bias. Attendees at the
weekly Outpatient Clozapine Clinics were approached to
participate in this research by a pharmacist. The study was
verbally explained and a Participant Information Leaflet
was given to the patient to take home. At their next
attendance, one month later, participants were asked if
they had read the leaflet; if they had any questions; and
if they would be interested in participating. If the patient
agreed to participate, written and verbal information was
again provided on the study and written informed consent
obtained.
2.8. Assessments Performed. Once enrolled, demographics
including age, gender, education level, employment status,
smoking status, duration of clozapine treatment, and num-
ber of medications coprescribed were collected and health
literacy was assessed using the REALM-R [13] health literacy
assessment tool.
The patient was asked what forms of information they
could recall receiving about clozapine (leaflet, DVD, verbal
information, etc.) in the past, and their baseline knowledge
of clozapine was then assessed using the 28-point checklist as
part of a semistructured interview.
The pharmacist then provided the C&M PIL for the
patient to read, counselled the patient on the key information
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points about clozapine as per the checklist, and addressed any
queries or misconceptions arising.
The baseline knowledge checklist was immediately reap-
plied after counselling, any gaps identified were addressed by
the pharmacist, and the time taken for the entire intervention
was recorded.
At the next clinic visit (or at 1 month for patients
attending more frequently) participants were asked if they
had accessed or been given information about clozapine from
other sources (e.g., Internet, healthcare professionals, other
patients, or friends/family members) in the last month to
account for increased knowledge from sources other than
pharmacist counselling.
The checklist was reapplied, to ascertain how much of
the information was retained. Pharmacist counselling and
the provision of the C&M PIL were then repeated and the
checklist was applied a final time. The time taken for this
repeat intervention was also recorded.
Due to difficulty in recruitment, permission was sought
and obtained from the Ethics Committee to conduct inter-
views by telephone where patients were in agreement.
2.9. Sample Size Calculation. The estimated effect size
(10.84%) is based upon the Brosnan et al. study [9] in which
the average knowledge score for patients (𝑛 = 40) in the
questionnaire before intervention was found to be 8.16 out of
13 and after intervention was found to be 9.57 out of 13 (𝑝 <
0.01). A sample size of 40 patients was deemed necessary.
2.10. Statistical Analysis. TheStatistical Package for the Social
Sciences (SPSS) Version 20 (IBM Corp.) was used for data
analysis. Descriptive statistics include frequencies, percent-
ages, and mean values. Means are reported with standard
deviation (SD) where appropriate. Bivariate analyses were
conducted to determine any statistically significant relation-
ships between varying parameters, for example, REALM-
R score versus employment status. Pearson’s correlation
coefficient is reported for parametric data and Spearman’s
rho is used to describe correlations with nonparametric
data. Correlations were significant at the 0.05 level unless
otherwise specified.
3. Results
Twenty-seven patients agreed to participate in the study.
There were no drop-outs and no participants were lost to
follow-up. One participant did not have time to take part in
counselling after the first month and therefore had a two-
month gap between interviews whilst another attended the
clinic early due to a holiday and therefore had a three-week
gap between interviews.The results of these respondentswere
removed from final analysis.
3.1. Patient Demographics. Study participants were typically
male, nonsmokers, in their mid-forties, with at least some
post-secondary-school education but not in current employ-
ment, prescribed approximately five medications, and taking
clozapine for 5–10 years as shown in Table 1. All participants
identified as “white Irish” ethnicity.
3.2. Patient Recall of Clozapine Education Provided Prior
to Commencement of Treatment. When asked, 20% of par-
ticipants could not recall receiving any information about
clozapine prior to commencing. The majority of females
(90%) recalled receiving at least one form of information,
whilst 72% of males recalled receiving clozapine information
on initiating treatment.
3.3. Knowledge Scores and Changes in Knowledge Scores with
Counselling. The mean knowledge score (from a possible
maximum score of 28) was low at baseline for the initial
counselling session but had more than doubled by the
completion of the study as shown in Table 2. The range of
scores remained large throughoutwith the standard deviation
remaining relatively consistent.
Despite the statistically significant reduction in knowl-
edge scores in the month between assessments, all patients
gained knowledge overall from baseline to completion of the
study.
The differences before and after each of the two coun-
selling sessions were statistically significant, as was the mean
overall change in knowledge score from the baseline to the
final assessment and the drop in scores between counselling
sessions (see Table 3).
3.4. Knowledge of Adverse Effects of Clozapine. Many patients
in this study had good baseline knowledge of the indication,
purpose, and frequency of the blood tests required for
clozapine. At the conclusion of the study all patientswere fully
aware of these counselling points and there was an increase
in the percentage of respondents having a deeper knowledge
of details around this information, for example, what effect
clozapine can have on white blood cells and the significance
of a “green” blood result. This contrasts with other studies
which have reported poor knowledge of the nature and
purpose of haematological monitoring with clozapine, with
almost half of patients in one study having no understanding
of the rationale for the blood tests and less than one in
five having adequate understanding [14]. The low scores for
knowledge of side effects are also in keeping with the findings
of Macpherson et al. [5]
3.5. Knowledge of Smoking Interaction Amongst Smokers.
In the smokers group, three of the seven participants in
the group (42.9%) were unable to identify the clinically
significant interaction between tobacco smoke and clozapine
prior to counselling and six of the seven participants (85.7%)
identified the interaction by the end of the study.
Only two of the eighteen nonsmoking participants (11.1%)
were aware of the interaction prior to counselling. At the end
of the study, fifteen (83.3%) of these participants correctly
identified smoking as having an interaction potential with
clozapine. This is of relevance as exposure to tobacco smoke
can impact upon clozapine plasma levels in nonsmokers also.
3.6. Health Literacy Assessment. The REALM-R assessment
of health literacy did not highlight any deficits and it appears
that the majority of participants had adequate health literacy.
Only one patient would be considered at risk for limited
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Table 1: Study participant demographics.
Study participant demographics 𝑛 = %
Gender
Female 10 40
Male 15 60
Age (years)
Mean (standard deviation) 45.08 (9.82)
Range 32–63
Level of education obtained
Primary school 2 8
Junior certificate 1 4
Leaving certificate — —
College/further education 7 28
University undergraduate degree 8 32
University postgraduate qualification 3 12
Master’s degree 4 16
Employed
Full time 3 12
Part time 6 24
No 16 64
Smokers 7 28
Years on clozapine
<0.5 1 4
0.5–1 — —
1–5 6 24
5–10 12 48
>10 6 24
Number of prescribed medications
Mean (standard deviation) 5.48 (4.49)
Range 1–18
health literacy as per the REALM-R assessment (see Table 4).
The knowledge checklist results and the overall change in
score from baseline to completion for this participant did not
reach statistical significance compared to themean results for
other participants; and the patient’s scores remained within
one standard deviation of the mean.
3.7. Duration of Interview. Interview duration was deter-
mined from incomplete data obtained as not all timings were
noted. From 14 results obtained for the first interview, the
mean time taken was 35.5 minutes, SD 5.6 (range 27–44
minutes). For the second interview, 15 results were recorded
and the mean time taken was 22.3 minutes, SD 4.4 (range
16–32 minutes). Counselling was completed in a “real world”
context inclusive of general discussion and counselling about
nonclozapine medications; therefore interview times spent
specifically on clozapine counselling were not clearly defin-
able.
3.8. Associations between Variables of Interest and Knowl-
edge. Female patients were prescribed higher numbers of
medications (𝑡 = 2.667, 𝑝 = 0.014); however, there was no
statistically significant difference between male and female
knowledge scores, and gender was not associatedwith change
in knowledge scores.
There was a moderate negative correlation between age
and precounselling scores one month after the first coun-
selling session which was found to be statistically significant
(𝑟 = −0.551, 𝑝 = 0.004) but the difference between older
and younger patients after the second counselling session was
not statistically significant. Older patients reported accessing
information between counselling sessions to a lesser degree
than younger patients (𝑡 = −0.2738, 𝑝 = 0.020) and were
prescribed higher numbers of medications (𝑟 = 0.560, 𝑝 =
0.004).
Education had a moderate positive correlation for the
change in knowledge score before and after the first coun-
selling session (rho = 0.459, 𝑝 = 0.021) but no effect on
individual knowledge scores or on any other variables. The
number of medications prescribed (𝑟 = −0.557, 𝑝 = 0.004)
was moderately negatively correlated with scores one month
after the first counselling session. None of the females in this
sample were smokers. There was no statistically significant
difference between smoker and nonsmoker scores and smok-
ing status did not correlate with change in knowledge scores.
The number of years’ participants had been prescribed
clozapine did not correlate with any other variables. Patients
were asked whether they had accessed any information
about clozapine between counselling sessions. Only four
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Table 2: Mean pre- and postcounselling knowledge scores (𝑛 = 25).
First counselling session
Baseline knowledge score (T1)
Mean score 9.16
Range 2–17
Standard deviation 4.53
First postcounselling score (T2)
Mean score 17.22
Range 5–26
Standard deviation 5.41
Second counselling session
Knowledge score 1 month after counselling (T3)
Mean score 14.36
Range 2–22
Standard deviation 5.27
Second postcounselling score (T4)
Mean score 20.24
Range 11–27
Standard deviation 4.48
T1 = baseline knowledge score; T2 = first postcounselling knowledge score;
T3= knowledge score 1month after counselling; T4= secondpostcounselling
knowledge score.
patients had done so: two had searched the Internet, one
had discussed it with a family member, and one with their
doctor. Their scores were not statistically different from that
of participants who had not sought further information
after the first counselling session. No statistically significant
difference was found in the knowledge scores of those
interviewed/counselled by telephone and those counselled in
person.
Employment status was positively associated with
REALM-R (𝑟 = 0.480, 𝑝 = 0.015) but not with any other
variables.
4. Discussion
Of the 25 participants in this study, 60% were male. The
prevalence of schizophrenia is generally reported to be higher
in males than in females and, due to the younger age
of onset, males may be overrepresented in first admission
schizophrenia studies; however there may be little difference
in the lifetime prevalence between males and females [15].
This is similar to the proportion of males attending the clinic
as a whole (62%) and also broadly in line with the gender
distribution in three of the five studies examined in the
literature review [4, 5, 7].
The average age was 45 years. This was largely similar
to two studies [5, 7] and somewhat similar to a third [6].
Schizophrenia commonly presents in early adulthood but
studies have shown that treatment with clozapine is delayed
by an average of four years despite clear guidelines regarding
its place in treatment [16]. In this sample, 24% of participants
had been taking clozapine for over 10 years and 72% for over
5 years.
Increasing age correlated with lower knowledge scores
after the one-month gap of pharmacist counselling but that
difference was not significant after the second counselling
session. It appears therefore that the drop in scores was
compensated for by the conclusion of the second counselling
session. A third interview may have been useful to validate
this effect. As might be anticipated, increasing age correlated
strongly with increased number of medications for comor-
bidities.
Level of education attained was found to correlate with
improvements in the first counselling session but not with
the initial postcounselling score alone; that is, the effect of
these participants was not large enough to affect the overall
initial postcounselling score and the effect of education was
not statistically significant thereafter. Only three patients with
educational levels less than post-secondary education were
part of this sample; therefore further research is required
to confirm this effect. Education may be considered as a
proxy indicator of health literacy in the absence of specific
health literacy assessments [17]. Jarernsiripornkul et al. [7]
found higher education to have a significant association with
increased knowledge at baseline and after counselling, whilst
Macpherson et al. [5] identified a positive association with
years of full-time education and knowledge in all groups
immediately after counselling and at assessment one month
later but, in keeping with results presented here, it did not
reach statistical significance.
A positive correlation between employment and health
literacy was identified in this study in line with other research
[17]. Fewer than 30% of participants in this study were
smokers, which is below the average smoking prevalence of
80% in patients with schizophrenia reported in the literature
[18]. Patients in our cohort were prescribed a mean of 5.48
(SD 4.49) medications which would indicate polypharmacy.
The effect of increasing pill burden upon side effects is well
documented as is its effect upon medication adherence [19,
20]. The number of medications prescribed and age were
each negatively correlated with the precounselling score after
one month. Further study is indicated in order to determine
the distinct effects of these variables on knowledge retention.
Previous studies [3, 4, 6] have reported age to be strongly
associated with knowledge of medication. Macpherson et al.
[5] considered the impact of antipsychotic dose on knowledge
and reported it to have a statistically significant effect, but
Jarernsiripornkul et al. [7] did not find a number ofmedicines
to have a statistically significant impact on knowledge scores.
More medications may indicate more severe illness, more
comorbidity, and may lead to an increased risk of adverse
effects. Interestingly, Macpherson et al.’s [5] results suggest a
positive correlation of higher doses with the recall of infor-
mation and that there is a strong link between medication
dose and change in knowledge scores (which they label as
educability).Higher doses of psychotropicmedicationsmight
be expected to be prescribed in more unwell patients and
to lead to impairment of memory due to adverse effects
such as sedation. In fact, the opposite may be true in
practice as effective treatment of schizophrenia may lead to
improvements in cognitive functioning [21]. This interaction
of medication dose, symptoms, and knowledge score can
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Table 3: Changes in knowledge scores.
Change in score (as a % of max. score) Test of statistical significance
Change in knowledge score after first counselling session (T2-T1)
Mean change 8.00
28.57% 𝑡 = 8.69, 𝑝 < 0.001Range 0–17
Standard deviation 4.60
Change in knowledge score one month after first counselling session (T3-T2)
Mean change −2.80
−10.00% 𝑡 = 2.99, 𝑝 = 0.006Range −13–4
Standard deviation 4.68
Change in knowledge score after second counselling session (T4-T3)
Mean change 5.84
20.86% 𝑡 = 8.92, 𝑝 < 0.001Range 1–14
Standard deviation 3.28
Overall change in knowledge score (T4-T1)
Mean change 11.04
39.43% 𝑡 = 13.10, 𝑝 < 0.001Range 5–22
Standard deviation 4.25
T1 = baseline knowledge score; T2 = first postcounselling knowledge score; T3 = knowledge score 1 month after counselling; T4 = second postcounselling
knowledge score.
Table 4: REALM-R health literacy assessment scores.
REALM-R score 𝑛 = %
6 1 4
7 7 28
8 (maximum) 17 68
A score of 6 or less should be considered to be at risk for poor health literacy.
also be expected to change over time as the patients’ dose is
titrated, or as symptoms change with age or external effects.
Whilst it is estimated that 40% of Irish adults have limited
health literacy [22], only 4% of this sample population were
found to be at risk for poor health literacy. The REALM-R
was chosen for its brevity given the extent of the engage-
ment required of the participant in the study. Although the
REALM-R has been correlated with the 66-item REALM
[13], neither has been validated in a population of patients
with schizophrenia.The large proportion of participants with
higher levels of education is also likely to have affected the
REALM-R score.
In order to assess the health literacy of this small sample,
the bar for REALM-R score was set at seven out of a
maximum of eight. With this adjustment, a higher REALM-
R score was associated with a higher baseline score; however,
the result was only marginally significant. There was no
association with change in knowledge score. Collins et al. [6]
found REALM score to be strongly correlated with higher
baseline knowledge score but, as is suggested in this study,
not with improvements in score after counselling. Schmitt
et al. [3] found adequate to marginal health literacy or “at
least some college education” to be strongly correlated with
knowledge in their retrospective cross-sectional study. A
larger samplewould be advisable in order to draw conclusions
directly from the health literacy scores obtained in this study.
The difference between the mean increases after each
pharmacist counselling session was statistically significant;
therefore it can be said that repeated counselling demon-
strated benefits over a single counselling intervention.
Controlling for all other variables, the effect of initial
baseline results on total improvement was significant; that is,
the higher the initial baseline score, the less the improvement
attained overall. Consequently, the participants who scored
lower at the initial baseline assessment attained greater
increases by the end of the study. This is not unexpected,
as lower scoring participants had greater scope for gaining
knowledge but it also indicates that those with least knowl-
edge at baseline may have the most to gain from pharmacist
counselling. Other studies reviewed did not comment on
whether this was the case in their results but Macpherson et
al. [5] did identify a cohort of patients that scored minimally
at baseline and follow-up and suggest that there may be
subgroup unable to benefit from education. In this study
two pharmacist counselling sessions led to sustained higher
scores supporting their [5] finding against using a single
explanatory session in favour of more prolonged educa-
tion. Macpherson et al. [5] also contend that “intermittent
booster education sessions are likely to consolidate learning”
which is somewhat supported by the findings of this study;
however longitudinal studies are indicated to confirm these
conclusions. Contrary to their findings in patients with
schizophrenia where a subgroup of patients scoredminimally
at baseline and follow-up which the authors attribute to the
complex “relationships between cognition, educability, and
schizophrenic symptomology” [5], this study found that all
patients benefited from counselling. Although the benefit was
not uniformly distributed, pharmacist counsellingwas shown
to be beneficial for knowledge gain in all participants. Many
patients did report trouble with memory and found it hard to
maintain concentration for the course of the intervention but
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the results demonstrate there are benefits even for patients
shown to be at increased risk for low knowledge (i.e., older
patients who are prescribed more medications).
4.1. Limitations. Twenty-seven patients from a total of 82
clinic attendees (32.9%) agreed to participate in the study.
Two participants were excluded from the results as the gap
between counselling sessions was more or less than one
month. Larger numbers would be desirable in order to
increase the generalizability of the study results.
Counselling sessions consisted of general discussions
about mental health and nonclozapine medication queries
as well as the counselling intervention of interest. It was
therefore difficult to ascertain the specific clozapine coun-
selling intervention time and to determine the cost-benefits
of pharmacist time spent on clozapine counselling. However,
the naturalistic counselling methods make the outcomes
more applicable to “real world” pharmacist counselling. The
involvement of three pharmacists in the counselling also
improves the generalizability of this intervention.
5. Conclusion
All participants in this study gained knowledge of clozapine
as a result of pharmacist counselling, which adds to the
evidence that pharmacist counselling can improve patient
knowledge of medication in a broad range of patient groups.
This study also demonstrates that a proportion of the
knowledge gained was preserved over time and that rein-
forcement of information leads to further gains.
Health literacy and illness factors may impact upon
patient knowledge and should be considered when coun-
selling patients, particularlywhenprovidingwritten informa-
tion. This study provides some evidence that improvements
in knowledge are not limited by baseline health literacy;
however further research is needed to confirm this view.
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